Meet our Board of Directors
Benedikt von Braunmühl - Chairman
Mr. Benedikt Von Braunmühl serves as CEO of the Synevo Division at Medicover. Mr. Von Braunmühl has held several high-profile healthcare consulting and advisory roles for companies across the globe supporting geographic expansion, business development, and mergers and acquisitions projects. Mr. Von Braunmühl previously was Senior Vice President – Global Commercial Operations of Qiagen NV, a leading European biotechnology company active in molecular diagnostics and life science markets. Mr. Von Braunmühl started his 25-year healthcare career at AstaMedica and has held various marketing and sales positions in the healthcare industry as well as in investment banking. Mr. Von Braunmühl holds a Bachelor Degree in Business Administration from the Graduate School of Business Administration in Zurich, Switzerland.
Bernard Courtieu, DVM, MBA
Christiane Honisch, PhD
Dr. Christiane Honisch is currently Head of Global Business Intelligence and Development at Eppendorf AG, a leading Life Science company. She has over 15 years of experience developing markers, assays, software and cutting-edge technology for Life Science applications and infectious disease detection, monitoring and characterization. She was formerly the Director of Microbiology Markets at Illumina, Inc. where she was responsible for the development of the company’s next-generation sequencing microbiology and virology market strategy. Prior to this she was the Director of Infectious Disease Research at Roche Molecular Diagnostics responsible for IVD research and microbial surveillance. Her team received the Roche Innovation Award in 2014. Previously she was a key individual in developing the commercial use of nucleic acid based mass spectrometry for DNA sequencing and microbial analysis at Sequenom, Inc. Dr. Honisch holds a diploma in chemistry and received her Ph.D. in molecular biology and microbiology from the University Carolo-Wilheimina zu Braunschweig, Germany and the German National Center for Biotechnology (GBF) in the field of the diagnosis and typing of tuberculosis.
Thierry Laugel, PhD, MBA
Dr. Thierry Laugel, Ph.D. is a co-Founder and Managing Partner at Kurma Partners since 2009. He was previously Partner at AGF Private Equity, (2006 to 2009) and CDC Innovation (1998 to 2005). Before that, he worked for Flamel Technologies as Project Director for Pharmaceutical R&D (1997-1998) and Fournier Japan, as Coordinator of R&D programmes (1992 – 1996). He has served as Director or Board member in more than 20 companies. Dr. Laugel holds a Pharm.D, a Ph.D. in Pharmacology, and an M.B.A. from INSEAD.